Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597472 | 0.85 | ALDH1A1 (0.40) | ALDH1A1KDM4CPTGER3DAOTSHR | |
| SCHEMBL1598325 | 0.83 | ALDH1A1 (0.39) | ALDH1A1GRM4DAOKDM4EALOX15 | |
| SCHEMBL10620249 | 0.79 | ALDH1A1 (0.41) | ALDH1A1KDM4CKDM4EALOX15SMN1; SMN2 | |
| SCHEMBL7528234 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4CPTGER3TSHRKDM4E | |
| SCHEMBL5308318 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KDM4CMAPTGAA | |
| SCHEMBL11827573 | 0.78 | ALDH1A1 (0.38) | ALDH1A1KDM4CDAOTSHRKDM4E | |
| SCHEMBL11816671 | 0.78 | ALDH1A1 (0.50) | ALDH1A1KDM4CGRM4DAOTSHR | |
| SCHEMBL6798684 | 0.73 | HSD17B2 (0.40) | ALDH1A1KDM4CGAA | |
| SCHEMBL6786610 | 0.73 | HSD17B2 (0.40) | ALDH1A1KDM4CGAA | |
| SCHEMBL6798968 | 0.73 | HSD17B2 (0.40) | ALDH1A1KDM4CGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0037672-B1 | PROCESS FOR THE PREPARATION OF CHIRAL HYDANTOINS, AND A NOVEL HYDANTOIN PRODUCED BY SAID PROCESS AND A PHARMACEUTICAL COMPOSITION CONTAINING IT | PFIZER INC. (US) | 1986-05-14 | — | — | EP | claimed |
| EP-0037672-A2 | Process for the preparation of chiral hydantoins, and a novel hydantoin produced by said process and a pharmaceutical composition containing it | PFIZER INC. (US) | 1981-10-14 | — | — | EP | claimed |
| US-4286098-A | HYPOGLYCEMIC AGENTS, TREATMENT OF DIABETES COMPLICATIONS | PFIZER INC. (US) | 1981-08-25 | — | — | US | claimed |
| JP-6343483-A | — | — | None | — | — | JP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| JP-H06343483-A | PRODUCTION OF L-HOMOPHENYLALANINE | AJINOMOTO CO INC | 1994-12-20 | — | — | JP | disclosed |
| US-4419521-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1983-12-06 | — | — | US | disclosed |
| US-4348526-A | COMPLICATIONS OF DIABETES | PFIZER INC. (US) | 1982-09-07 | — | — | US | disclosed |
| EP-0037672-A2 | Process for the preparation of chiral hydantoins, and a novel hydantoin produced by said process and a pharmaceutical composition containing it | PFIZER INC. (US) | 1981-10-14 | — | — | EP | disclosed |
| US-4286098-A | HYPOGLYCEMIC AGENTS, TREATMENT OF DIABETES COMPLICATIONS | PFIZER INC. (US) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | ALDH1A1 294/4885KDM4C 1398/4885PTGER3 452/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | ALDH1A1 1250/4885KDM4C 2851/4885PTGER3 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.